

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1. (Currently amended) A method of administering recombinant adeno-associated virus (rAAV) virions to a human, comprising:

(a) providing at least one rAAV virion, said at least one rAAV virion comprising a vector further comprising a heterologous nucleic acid sequence comprising a gene encoding Factor IX, which sequence results in a therapeutic effect when delivered to said human; and

(b) delivering said rAAV virions to the bile duct system or to the ducts of the submandibular gland of said human under conditions wherein said heterologous nucleic acid sequence is expressed at a therapeutic level, wherein said human has preexisting anti-AAV antibodies.

2. (Original) The method of claim 1, wherein said preexisting anti-AAV antibodies are anti-AAV-2 antibodies.

3-5. (Cancelled)

6. (Previously presented) The method of claim 1, wherein said Factor IX is secreted into an extracellular space.

7. (Previously presented) The method of claim 1, wherein said Factor IX is secreted into a blood vessel.

8-12. (Cancelled)

13. (Currently amended) A method of treating hemophilia in a human, comprising:

(a) providing at least one recombinant adeno-associated virus (rAAV) virion, said rAAV virion comprising a vector further comprising a heterologous nucleic acid sequence further comprising a gene encoding Factor IX; and

(b) delivering said rAAV virions to the bile duct system or to the ducts of the submandibular gland of said human under conditions wherein said gene is expressed at a therapeutic level, wherein said human has preexisting anti AAV antibodies.

14. (Original) The method of claim 13, wherein said preexisting anti-AAV antibodies are anti-AAV-2 antibodies.

15. (Cancelled)

16. (Previously presented) The method of claim 13, wherein said Factor IX is human Factor IX.

17. (Previously presented) The method of claim 13, wherein said Factor IX is secreted into an extracellular space.

18. (Previously presented) The method of claim 13, wherein said Factor IX is secreted into a blood vessel.

19. (Original) The method of claim 17, wherein said Factor IX is human Factor

IX.

20. (Original) The method of claim 18, wherein said Factor IX is human Factor IX.

21-26. (Cancelled)

27. (New) A method of administering recombinant adeno-associated virus (rAAV) virions to a human, comprising:

(a) providing at least one rAAV virion, said at least one rAAV virion comprising a vector that comprises a heterologous nucleic acid sequence which sequence results in a therapeutic effect when delivered to said human; and

(b) delivering said rAAV virions to the bile duct system or to the ducts of the submandibular gland of said human under conditions wherein said heterologous nucleic acid sequence is expressed at a therapeutic level, wherein said human has preexisting anti-AAV antibodies.

28. (New) The method of claim 27, wherein said preexisting anti-AAV antibodies are anti-AAV-2 antibodies.